Efficacy and Safety of Inclisiran in Patients with Polyvascular Disease: Pooled, Post Hoc Analysis of the ORION-9, ORION-10, and ORION-11 Phase 3 Randomized Controlled Trials

Atlas Writing G, Esc Atlas of Cardiology is a compendium of cardiovascular statistics compiled by the European Heart Agency adotESoC, Developed in collaboration with the national societies of the European Society of Cardiology member c, Timmis A, Townsend N, Gale CP, et al. European Society of Cardiology: Cardiovascular Disease Statistics 2019 (Executive Summary). Eur Heart J Qual Care Clin Outcomes. 2020;6(1):7–9.

Article  Google Scholar 

Khera R, Valero-Elizondo J, Nasir K. Financial toxicity in atherosclerotic cardiovascular disease in the United States: current state and future directions. J Am Heart Assoc. 2020;9(19):e017793.

Article  Google Scholar 

Ning H, Kershaw KN, Allen NB, Wilkins J, Lloyd-Jones DM. Association of health-related quality of life with atherosclerotic cardiovascular disease: lifetime risk pooling project. Am J Prev Cardiol. 2021;7:100222.

Article  Google Scholar 

Pinheiro LC, Reshetnyak E, Sterling MR, Richman JS, Kern LM, Safford MM. Using health-related quality of life to predict cardiovascular disease events. Qual Life Res. 2019;28(6):1465–75.

Article  Google Scholar 

Sajobi TT, Wang M, Awosoga O, Santana M, Southern D, Liang Z, et al. Trajectories of health-related quality of life in coronary artery disease. Circ Cardiovasc Qual Outcomes. 2018;11(3):e003661.

Article  Google Scholar 

Yakubov S. Polyvascular atherosclerotic disease: recognizing the risks and managing the syndrome. Curr Med Res Opin. 2009;25(11):2631–41.

Article  CAS  Google Scholar 

Weissler EH, Jones WS, Desormais I, Debus S, Mazzolai L, Espinola-Klein C, et al. Polyvascular disease: a narrative review of current evidence and a consideration of the role of antithrombotic therapy. Atherosclerosis. 2020;315:10–7.

Article  CAS  Google Scholar 

Gutierrez JA, Aday AW, Patel MR, Jones WS. Polyvascular disease: reappraisal of the current clinical landscape. Circ Cardiovasc Interv. 2019;12(12):e007385.

Article  Google Scholar 

Aday AW, Matsushita K. Epidemiology of peripheral artery disease and polyvascular disease. Circ Res. 2021;128(12):1818–32.

Article  CAS  Google Scholar 

Bhatt DL, Eagle KA, Ohman EM, Hirsch AT, Goto S, Mahoney EM, et al. Comparative determinants of 4-year cardiovascular event rates in stable outpatients at risk of or with atherothrombosis. JAMA. 2010;304(12):1350–7.

Article  CAS  Google Scholar 

Colantonio LD, Hubbard D, Monda KL, Mues KE, Huang L, Dai Y, et al. Atherosclerotic risk and statin use among patients with peripheral artery disease. J Am Coll Cardiol. 2020;76(3):251–64.

Article  Google Scholar 

Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2019;73(24):e285–350.

Article  Google Scholar 

Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41(1):111–88.

Article  Google Scholar 

Miao B, Hernandez AV, Alberts MJ, Mangiafico N, Roman YM, Coleman CI. Incidence and predictors of major adverse cardiovascular events in patients with established atherosclerotic disease or multiple risk factors. J Am Heart Assoc. 2020;9(2):e014402.

Article  CAS  Google Scholar 

Bonaca MP, Hamburg NM, Creager MA. Contemporary medical management of peripheral artery disease. Circ Res. 2021;128(12):1868–84.

Article  CAS  Google Scholar 

Jukema JW, Szarek M, Zijlstra LE, de Silva HA, Bhatt DL, Bittner VA, et al. Alirocumab in patients with polyvascular disease and recent acute coronary syndrome: ODYSSEY OUTCOMES trial. J Am Coll Cardiol. 2019;74(9):1167–76.

Article  CAS  Google Scholar 

Silverman MG, Ference BA, Im K, Wiviott SD, Giugliano RP, Grundy SM, et al. Association between lowering LDL-C and cardiovascular risk reduction among different therapeutic interventions: a systematic review and meta-analysis. JAMA. 2016;316(12):1289–97.

Article  CAS  Google Scholar 

Ference BA, Ginsberg HN, Graham I, Ray KK, Packard CJ, Bruckert E, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2017;38(32):2459–72.

Article  CAS  Google Scholar 

Ray KK, Molemans B, Schoonen WM, Giovas P, Bray S, Kiru G, et al. EU-wide cross-sectional observational study of lipid-modifying therapy use in secondary and primary care: the DA VINCI study. Eur J Prev Cardiol. 2021;28(11):1279–89.

Article  Google Scholar 

Khunti K, Danese MD, Kutikova L, Catterick D, Sorio-Vilela F, Gleeson M, et al. Association of a combined measure of adherence and treatment intensity with cardiovascular outcomes in patients with atherosclerosis or other cardiovascular risk factors treated with statins and/or ezetimibe. JAMA Netw Open. 2018;1(8):e185554.

Article  Google Scholar 

Brandts J, Ray KK. Low-density lipoprotein cholesterol-lowering strategies and population health: time to move to a cumulative exposure model. Circulation. 2020;141(11):873–6.

Article  Google Scholar 

Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017;376(18):1713–22.

Article  CAS  Google Scholar 

Schwartz GG, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R, et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med. 2018;379(22):2097–107.

Article  CAS  Google Scholar 

Khvorova A. Oligonucleotide therapeutics - a new class of cholesterol-lowering drugs. N Engl J Med. 2017;376(1):4–7.

Article  CAS  Google Scholar 

Wright RS, Ray KK, Raal FJ, Kallend DG, Jaros M, Koenig W, et al. Pooled Patient-Level Analysis of inclisiran trials in patients with familial hypercholesterolemia or atherosclerosis. J Am Coll Cardiol. 2021;77(9):1182–93.

Article  CAS  Google Scholar 

Ray KK, Wright RS, Kallend D, Koenig W, Leiter LA, Raal FJ, et al. Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol. N Engl J Med. 2020;382(16):1507–19.

Article  CAS  Google Scholar 

Raal FJ, Kallend D, Ray KK, Turner T, Koenig W, Wright RS, et al. Inclisiran for the treatment of heterozygous familial hypercholesterolemia. N Engl J Med. 2020;382(16):1520–30.

Article  CAS  Google Scholar 

Fitzgerald K, White S, Borodovsky A, Bettencourt BR, Strahs A, Clausen V, et al. A highly durable RNAi therapeutic inhibitor of PCSK9. N Engl J Med. 2017;376(1):41–51.

Article  CAS  Google Scholar 

Bonaca MP, Nault P, Giugliano RP, Keech AC, Pineda AL, Kanevsky E, et al. Low-density lipoprotein cholesterol lowering with evolocumab and outcomes in patients with peripheral artery disease: insights from the FOURIER trial (further cardiovascular outcomes research with PCSK9 inhibition in subjects with elevated risk). Circulation. 2018;137(4):338–50.

Article  CAS  Google Scholar 

Lin I, Sung J, Sanchez RJ, Mallya UG, Friedman M, Panaccio M, et al. Patterns of statin use in a real-world population of patients at high cardiovascular risk. J Manag Care Spec Pharm. 2016;22(6):685–98.

Google Scholar 

Baum SJ, Rane PB, Nunna S, Habib M, Philip K, Sun K, et al. Geographic variations in lipid-lowering therapy utilization, LDL-C levels, and proportion retrospectively meeting the ACC/AHA very high-risk criteria in a real-world population of patients with major atherosclerotic cardiovascular disease events in the United States. Am J Prev Cardiol. 2021;6:100177.

Article  Google Scholar 

Bonaca MP, Gutierrez JA, Cannon C, Giugliano R, Blazing M, Park J-G, et al. Polyvascular disease, type 2 diabetes, and long-term vascular risk: a secondary analysis of the IMPROVE-IT trial. Lancet Diabetes Endocrinol. 2018;6(12):934–43.

Article  Google Scholar 

Wang N, Woodward M, Huffman MD, Rodgers A. Compounding benefits of cholesterol-lowering therapy for the reduction of major cardiovascular events: systematic review and meta-analysis. Circ Cardiovasc Qual Outcomes. 2022;101161CIRCOUTCOMES121008552.

DeTora LM, Toroser D, Sykes A, Vanderlinden C, Plunkett FJ, Lane T, et al. Good Publication Practice (GPP) guidelines for company-sponsored biomedical research: 2022 update. Ann Intern Med. 2022.

留言 (0)

沒有登入
gif